ABSTRACT

Background: The evolution of asthma starting in childhood varies and depends on a series of factors (atopy, allergens, and environmental irritants, etc). Treatment may influence the evolution of the disease and even cause the symptoms to disappear. However, there remains a risk of relapse years later.

Objectives: To assess the role of bronchial hyperresponsiveness in asthma relapse in young adulthood in patients with symptoms that disappeared after treatment prescribed in childhood.

Material and methods: To determine the evolution of asthma and patients' personal opinions, 78 patients were sent a questionnaire several years after having been discharged without symptoms in the previous 2 years, and without the need for medication. The methacholine test was used to evaluate bronchial hyperresponsiveness at discharge. The 40 patients who correctly completed the questionnaire were divided into three groups according to the methacholine dose required to obtain a 20% decrease in forced expiratory volume in 1 second (PD20): group 1 (15 patients), < 1000 μg; group 2 (10 patients) between 1001 and 2000 μg; and group 3 (15 patients) > 2100 μg. The mean age at discharge was 16 years (range 13-25 years) versus 26 years at the time of response (range 18-33 years), with a similar distribution in all three groups. Age at disease onset, with estimation of severity, age at the first visit and at the start of treatment, and respiratory function were evaluated.

Results: Thirty of the interviewed patients considered themselves to be cured. Seven of the patients (three in group 1, one in group 2, and three in group 3) did not consider themselves to be cured, although their symptoms were minimal and they rarely used medication. Health status was described as “regular” with sporadic symptoms by one patient in each group. No correlation with methacholine response was observed.

Conclusion: No relationship was found between the degree of bronchial hyperresponsiveness and the risk of relapse in young adults who suffered asthma in childhood.


Asthma starting in childhood can evolve in different ways\(^1\), though the persistence or reappearance of the disease in adulthood is dependent upon very diverse factors, some of which are well known, though others may go unnoticed due to difficulties in evaluating them or to special situations of concrete individuals, ethnic groups, climates or occupational environments, among others. The remission or relapse rates are highly variables in the different studies published, possibly because of differences in the populations studied, in the diagnostic criteria employed, or in the treatments prescribed\(^2,3\). Application of the term “natural history” in reference to the evo-
lution of the disease is not fortunate, since it implies spontaneous evolution without therapeutic intervention. Paradoxically, most follow-up studies make no reference to the treatment followed by the included patients, though it must be assumed that the medication and environmental measures adopted will have played a relevant role in the development of the process. The parameters most commonly addressed in such studies comprise patient sex, atopy and respiratory function, and some authors also contemplate bronchial lability.

In most asthmatic children, atopic susceptibility is a key factor for development of the process, where an allergic etiology is accepted in up to 70% of cases. Inflammation of the respiratory mucosa secondary to the allergic reaction, and bronchial hyperresponsiveness, constitute the two main pathogenic factors of the allergic reaction, and bronchial hyperresponsiveness, constitute the two main pathogenic factors of the disease, which often begins manifesting locally in the form of rhinitis – thus requiring the investigation of possible bronchial lability.

The aim of the present study was to determine the opinion of patients regarding their asthmatic disease diagnosed in childhood, and that after several years without symptoms, had been discharged as cured. The initial severity at beginning the process and bronchial responsiveness at discharge were evaluated.

MATERIAL AND METHODS

A questionnaire was administered among patients diagnosed with extrinsic asthma and controlled for a number of years since childhood, with treatment according to the management options available in the years of disease control. The visits of the included patients had ceased after a minimum symptoms-free period of two years, without the need for medication, and all subjects were assessed for bronchial responsiveness based on the methacholine test performed at the time of medication suspension. Several years after the end of the controls, the patients were requested to answer the questionnaire to determine their health in relation to their previous asthmatic process (see Annex 1).

Patients

All the patients receiving the questionnaire met the following conditions: on the study made in the first visit in childhood, serum total IgE above the upper limit of normality for the age involved. Prick-test positive to one or more aeroallergens (predominance of dust house mites, followed by pollen of graminaceae, grasses, parietaria or olive, and Alternaria). In all patients, sensitization was confirmed via specific IgE testing (RAST).

The severity of the process was evaluated on the basis of the habitual need for treatment of the asthmatic crises, using the following criteria:

- Mild: no medical consultation usually required (self-controlled), with no alteration of daily life activities.
- Moderate: usually requires a medical visit, and alters daily life activities.
- Severe: emergency care or hospital admission required on more than one occasion.
- Very severe: admission to intensive care required on at least one occasion: status astmaticus.

Methacholine test

The abbreviated method of Yan was used, in which the aerosol is inhaled during inspiration, allowing quantification of the methacholine dose administered. The patients were asymptomatic on performing the methacholine provocation test, without bronchodilating or anti-inflammatory medication for at least the two preceding days, and with respiratory function parameters within the normal range, including FEV₁ > 70% the predicted value. Spirometry was carried out using the Vicatest Spimco (Mijnhardt, The Netherlands) before testing and two minutes after each of the inhalations (Mediprom FDC 88 dosimeter, Paris, France). With mouthpiece connection to the nebulizer (De Vilbiss 5610 D), the patients were allowed to breathe normally, and after forced exhalation were instructed to perform maximum inspiration (1-2 seconds), followed by a 3-second apneic period, and then gentle exhalation. The drop in FEV₁ was estimated from the value of this parameter recorded after inhalation of the saline solution with which the test is started. Dilutions of methacholine were prepared (Provocinhle, Roche) 1/100 with saline solution, yielding concentrations of 10 mg/ml. In the first inhalation 100 μg of methacholine were administered, followed by repeated dosing of 200 μg (cumulative dosage: 300 μg, 500 μg, 700 μg, 900 μg, etc.). The test ended when FEV₁ decreased 20% (PD20), calculated from the dose-response curve. Administration was suspended if this decrease was not observed with a maximum cumulative dose of 2100 μg.

Statistical analysis

Fisher’s exact test for small parametric samples was used, though some of the parameters with figures 5 were confirmed with the Chi Square Calculator.
RESULTS

Of the 78 questionnaires delivered to the home addresses reflected in the case histories, 9 (11.5%) were returned due to change in address, and 42 were answered (53.8%). Of these, two were found to be incomplete and were excluded. The first visit of all the children took place between 1978 and 1993, and patient age on that first visit ranged from one year and 10 months to 15 years. The symptoms of

| Age and clinical data of the three groups of patients with different intensity responses to methacholine testing |
|---|---|---|---|---|---|---|---|
| Group 1 | < 1000 μg | 1978 | 1 year | 2 mo. | S/VS: 11 | 80-940 μg | 14 children | Normal: 12 Decreased: 3 0 = 16.2 0 = 26.6 |
| -15 children | -11/4 | 1992 | 5 years | 0 = 2y 8m | S/V: 11 M: 3 M: 1 | | |
| Group 2 | 1001-2000 μg | 1980 | 4-15 years | 2-10 years | S: 3 M: 6 M: 1 | 1030-2000 μg | 8 children | Normal: 10 0 = 16.2 23-31 years 0 = 26.8 |
| -10 children | -7/3 | 1993 | 5y | | | |
| Group 3 | > 2000 μg | 1978 | 2 years | 4 months-8 years | S: 7 M: 7 M: 1 | 2000- > 2100 μg | 15 children | Normal: 13 Decreased: 2 0 = 16.0 0 = 26.28 |
| -15 children | -13/2 | 1993 | 8 years | 3y 4m | | |
| Grouped by: | Sensitivity to methacholine | Age at start of disease | Assessment of severity | Methacholine Range | Immunotherapy | Spirometry at discharge | Age at discharge | Age at response (range and (i) |
| | in μg | (1st visit) | at 1st visit | (FEV1/FVC) | | (range) | and (c) | (range) and (c) |
| S/VS, severe/very severe; M, moderate; Ml, mild. |

| Table II |
| Patient response to the study questionnaire |
|---|---|---|---|
| Working environment/Contamination | Sports | Smoker | Wheezing |
| Group 1 | Yes: 3 | Tolerated: 11 | No: 12 | Da: 0 |
| No: 12 | Not tolerated: 1 | None: 4 | Ra: 9 |
| Group 2 | Yes: 5 | Tolerated: 5 | No: 8 | Da: 0 |
| No: 6 | Not tolerated: 1 | None: 4 | Ra: 4 |
| Group 3 | Yes: 1 | Tolerated: 10 | No: 14 | Da: 0 |
| NO: 14 | None: 5 | No: 14 | Ra: 6 |

Da, daily; Ra, rarely; N, never; CInh, inhalatory corticoids.
asthma had started at ages between 2 months and 10 years, with an average of 3 years and 6 months (table I). The control of these patients ceased between the years 1991 and 2001.

Specific immunotherapy was the etiological treatment followed by 37 of the patients. Prophylactic, symptomatic or pathogenic treatment varied over the period of time in which the patients were controlled, depending on the habitual medication in each moment and the clinical condition of the patient. In all case, adoption of the pertinent environmental measures was recommended.

The global 40 children were divided into three groups according to the amount of methacholine required to reach PD20: group 1: < 1000 μg (very sensitive), 15 children; Group 2: 1001-2000 μg (moderately sensitive), 10 children; and Group 3: > 2000 μg (scantly sensitive), 15 children. Immunotherapy was prescribed in 14 children in group 1, 8 in group 2, and all 15 in group 3. Patient control continued up to an average age of 16.2 years (range 12-25), with a similar distribution in all three groups. At the end of the control period, respiratory function remained within normal limits (PEF, > 80 % and FMF 25-75 > 60 % of prescribed) in 78.5 % of the patients in group 1, in all the patients in group 2, and in 86.6 % of those in group 3.

The ages of the patients at the end of the controls and on answering the questionnaire were similar in all three groups, with an average of 16 years (range 12-22) at control cessation, and 26 years (range 18-31) at the time of the questionnaire. In this context, the responses were as follows (table II):

Table I: Distribution of patients in the groups according to the amount of methacholine required to reach PD20

<table>
<thead>
<tr>
<th>Groups</th>
<th>Methacholine Required (μg)</th>
<th>Number of Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>&lt; 1000</td>
<td>15</td>
</tr>
<tr>
<td>Group 2</td>
<td>1001-2000</td>
<td>10</td>
</tr>
<tr>
<td>Group 3</td>
<td>&gt; 2000</td>
<td>15</td>
</tr>
</tbody>
</table>

Table II: Distribution of patients according to the intensity of bronchial hyperresponsiveness

<table>
<thead>
<tr>
<th>Breathing difficulty</th>
<th>Cough</th>
<th>Rhinitis</th>
<th>Medication</th>
<th>How feels</th>
<th>Considers cured</th>
</tr>
</thead>
<tbody>
<tr>
<td>Da: 0</td>
<td>Da: 0</td>
<td>Da: 0</td>
<td>Da: 0</td>
<td>Da: 0</td>
<td>Da: 0</td>
</tr>
<tr>
<td>Ra: 6</td>
<td>Ra: 6</td>
<td>Ra: 6</td>
<td>Ra: 6</td>
<td>Ra: 6</td>
<td>Ra: 6</td>
</tr>
<tr>
<td>N: 9</td>
<td>N: 9</td>
<td>N: 9</td>
<td>N: 9</td>
<td>N: 9</td>
<td>N: 9</td>
</tr>
</tbody>
</table>

- Group 1 (very sensitive): Three works in a contaminated environment, and three are moderate smokers (< 10 cigarettes/day); 11 tolerate sports activities well, one does not tolerate such activity, and four do not participate in such activities. Sporadically, 9 suffer wheezing, 6 breathing difficulty, 8 cough, and 8 symptoms of rhinitis. On a daily basis, one suffers cough and three rhinitis. The use of medication is very limited, since 10 of the patients usually never require pharmacological treatment. Seven claim to feel very well, another 7 well, and one regular. In sum, 11 consider themselves to be cured; 3 do not consider themselves to be cured, and one patient describes personal condition as “regular”.

- Group 2 (moderately sensitive): Half of the subjects work in a contaminated environment, and two are smokers (15-20 cigarettes/day). Five tolerate sports activities, one does not, and four do not participate in such activities. Sporadically, four suffer wheezing, three breathing difficulty and cough, and four have symptoms of rhinitis. On a daily basis, only one patient suffers cough, and three rhinitis. Four patients never use medication, one uses topical antihistamines, and two sometimes a β2-agonist and/or inhaled corticoids. Six feel very well, three well, and one poorly. Eight patients consider themselves to be cured, one does not, and one patient describes personal condition as “regular”.

- Group 3 (scantly sensitive): Only one of these patients works in a contaminated environment, and one smokes no more than two cigarettes a day. Ten tolerate sports activities, while the remaining 5 do not practice sports. Sporadically, 6 suffer wheezing,
two breathing difficulty, 6 cough and 10 rhinitis. On a daily basis, only one patient coughs, and two present symptoms of rhinitis. Four sometimes use antihistamines, and one patient uses β₂-agonists.

Eight claim to feel very well and 7 well. Eleven patients consider themselves to be cured, three do not, and one patient describes personal condition as "regular".

No significant differences were recorded on comparing the results of the three groups in terms of the most characteristic symptoms of bronchial involvement (wheezing and breathing difficulty), and as refers to the opinion of the patients on their personal condition and whether or not they consider themselves to be cured.

Most of the patients in all three groups considered themselves to be cured (11, 8 and 11 subjects, respectively). One in each group considers healing to be incomplete ("regular"), due to the existence of sporadic symptoms. Lastly, three patients in group 1, one in group 2, and three in group 3 do not consider themselves to be cured. The characteristics of these patients are shown in table III.

### DISCUSSION

A range of factors are implicated in the appearance and progression of asthma, and their role is difficult to establish in each concrete case, due to the influence of genetic predisposition (atopy), patient life style habits and the characteristics of the environment (in the home, outdoors and at work). The age at onset of the disease, the persistence and severity of the symptoms, the presence of eczema as associated topical pathology, the timeliness and idoneity of treatment and its correct compliance, and patient gender (increased frequency among males in infancy, with female predominance at later ages), are all aspects to be taken into consideration in prognosis possible persistence or reappearance of the disease in the adult.\(^2\,3\,7\,13\,14\) Of all the underlying factors, special attention should focus on patient respiratory status – both static (spirometry) and functional (bronchial hyperresponsiveness)\(^7\,13\,15\).

Bronchial hyperresponsiveness is known to play a fundamental role in the pathogenesis of asthma, and it is difficult to establish a diagnosis in its absence.\(^16\,17\).

---

### Table III

<table>
<thead>
<tr>
<th>Group</th>
<th>Age at onset</th>
<th>Age 1st visit</th>
<th>Evaluation of severity</th>
<th>Diagnoses</th>
<th>Allergens</th>
<th>Other triggering factors</th>
<th>IgE (IU/ml)</th>
<th>PD20 µg</th>
<th>Methacholine</th>
<th>Respiratory function at discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2y-6m</td>
<td>8y-3m</td>
<td>Severe</td>
<td>Asthma, rhinitis, urticaria, drug allergy</td>
<td>Mites</td>
<td>IgE: 815</td>
<td>220</td>
<td>?</td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>18m</td>
<td>8y-8m</td>
<td>Severe</td>
<td>Asthma</td>
<td>Mites, Exercise</td>
<td>IgE: 164</td>
<td>830</td>
<td>Normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>3m</td>
<td>1y-10m</td>
<td>Severe</td>
<td>Asthma</td>
<td>Mites</td>
<td>IgE: 830</td>
<td>190</td>
<td></td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>5y</td>
<td>7y-9m</td>
<td>Severe</td>
<td>Asthma</td>
<td>Mites</td>
<td>IgE: 186</td>
<td>1590</td>
<td>Normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>5y</td>
<td>11y</td>
<td>Severe</td>
<td>Asthma</td>
<td>Mites, Intants</td>
<td>IgE: 483</td>
<td></td>
<td>&gt; 2000</td>
<td>Normal</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>10m</td>
<td>4y-9m</td>
<td>Severe</td>
<td>Asthma</td>
<td>Mites, Fungi</td>
<td>IgE: 360</td>
<td>2030</td>
<td>Normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3y</td>
<td>6y</td>
<td>Severe</td>
<td>Asthma, rhinitis</td>
<td>Mites, Pollen graminneas, olive and grasses</td>
<td>IgE: 741</td>
<td>&gt; 2100</td>
<td>Normal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Allergol et Immunopathol 2007;35(2):62-70*
The method most commonly used to evaluate the degree of bronchial hyperresponsiveness is based on the inhalation of methacholine at progressively increasing doses. A number of procedures have been developed to this effect, of which two are currently recommended: the Two-minute tidal breathing dosing protocol and the Five-breath dosimeter protocol. The effectiveness of the two protocols does not differ from that of other abbreviated methods, which are easy to perform and offer the advantage of providing a more accuracy of the methacholine dose administered.

The patients of this study were grouped according to their response to methacholine provocation as very sensitive (PD20 with \(<1000 \mu g\)g), moderate-sensitiv \(1000-2000 \mu g\), and scanty sensitive (PD20 > 2000 \mu g\). Apart from immunotherapy, which was the treatment common to almost all children, baseline therapy was provided according to the management guidelines applicable in the years when the patients were subjected to control – with variations in each case over time according to the clinical circumstances of each patient.

Despite the different responses to methacholine provocation or challenge in the three groups, the evolution of the patients between 6 and 15 years (mean = 10.4) after the cessation of routine control did not differ to any important degree. The only numerical difference of note was sporadically perceived breathing difficulty, which proved to be more frequent among the children in group 1 (most sensitive) than in group 3 (least sensitive) – though the difference was not statistically significant. The number of patients conforming the groups was possibly insufficient to demonstrate significant differences in the data collected by the questionnaire.

Since rhinitis is an associated process in practically all patients with asthma, and moreover considering that it is not always easy for patients to relate symptoms of rhinitis with the cause of allergy (most reporting rhinitis with less or greater frequency), we have avoided analyzing the responses to this item of the questionnaire.

Estimation of the severity of asthma has been the subject of a number of classifications, based on the frequency of the symptoms (seasonal incidence not being taken into consideration), the intensity of the...
asthmatic crises, or on patient respiratory function – though none of these evaluations are full satisfac-
tory22,24. The frequency and intensity of the asthmatic crises may be valid as a parameter for assessing
severity, as well as the need or not for medical con-
sultation or hospital admission, this being the para-
meter used in our patients on occasion of the first
visit21. Despite the fact that the percentage of pa-
tients classified as severe or very severe in group
1 was considerably greater than in group 3 (73.3 %
vs. 48.6 %), the difference failed to reach statistical
significance – possibly due to the reduced sample
size involved.

Based on this classification, and on occasion of
the first visit, 20 patients were considered to present
severe asthma (plus another case considered to be
very severe). Of these, 7 did not consider them-
seves to be cured, though contradictorily five
claimed to feel well, and almost all defined the symp-
toms as sporadic (Table III).

The future of patients who have suffered asthma
since childhood should be a matter of concern. The
evolution of the disease may be highly variable,
though it is largely dependent upon the timeliness
and idoneity of treatment. In the patients of our
study, the time lag between the onset of the disease
and patient age at the first visit is due to the fact that
most of the subjects were treated by their pediatri-
cian or by other specialists – with no specification
of the treatments prescribed. Methacholine testing
was carried out at discharge after at least two years with-
tout symptoms and without treatment, in order to ob-
tain an objective basis for establishing a long-term
prognosis, due to the possibility of relapse – with
rates that differ greatly in the different studies found
in the literature. In all cases, measures were advised
to avoid long-term relapse, stressing the need to
avoid smoking and working in contaminated environ-
ments (irritants, allergens). This could be referred to
as “fourth prevention”, as a complement to the pre-
ventive methods advocated in earlier ages and which
are defined as “primary, secondary and tertiary pre-
vention”25.

The three groups of patients were established ac-
cording to the degree of hyperresponsiveness,
which appeared to be the most objective parameter –
since other data may be difficult to evaluate, such as
family antecedents, the association of other aller-
gic processes, patient sex, exposure to aeroaller-
gens, environmental contaminants (external and oc-
cupational), or smoking, etc. Other studies, some
even published by the same authors26, differ in their
appraisal of the predictive value of bronchial respon-
siveness in relation to the future of the patients14,27.

Given the evolution of our patients, it can be de-
duced that the degree of bronchial responsiveness is
not adequate as a parameter on which to base the
middle-term prognosis of the risk of asthma reap-
pearance in patients with processes that started in
early childhood.

Different studies show that bronchial responsi-
veness improves with specific immunotherapy, with
correction of much of the imbalance between
Th1/Th2 lymphocytes – this being considerably al-
tered in atopic subjects24,25. In this sense, the pa-
tients in our third group possibly could have benefit-
ed from immunotherapy, since they required over
2000 μg of methacholine to reach PD20, and some
even failed to reach this point with the maximum ad-
ministered dose – despite the fact that in 7 of them
asthma was initially classified as severe, and moder-
ate in another 7.

In conclusion, no correlation was found between
the degree of bronchial hyper-responsiveness and
the risk of relapse in young adults who suffered asth-
ma in childhood. We consider that the favorable evo-
lution of the patients is largely attributable to the spe-
cific treatment prescribed as soon as the etiological
diagnosis of the process is established, together
with the introduction of other measures that always
should be decided as soon as possible30,32.

ACKNOWLEDGEMENTS

The author thanks Dr. Martín Rios-Alcolea, head
of the Department of Statistics of the Faculty of Bio-
logy (University of Barcelona) for his valuable con-
tribution to this study.

REFERENCES

1. Martínez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M,
Morgan WJ. Asthma and wheezing in the first six years of life.
3. Sears MR, Greene JM, Willan AR, Wlezien EM, Taylor DR,
Flannery EM et al. A longitudinal, population-based, cohort
study of childhood asthma followed to adulthood. N Engl J
4. Vilhams NJ, Law L, Chilcote ST, Clough JB. The natural histo-
ry of respiratory symptoms in a cohort of adolescents. Am J
5. De Marco R, Locatelli F, Cerveri I, Bugiani M, Marinoni A, Gi-
ammano G, et al. Incidence and remission of asthma. A re-
trospective study on the natural history of asthma in Italy. J Al-
6. Reed CE. The natural history of asthma. J Allergy Clin Im-
munol. 2006;118:543-8
7. Grof MH, Garrisson J, Postma DS. Asthma: from childhood to


Annex 1

Data for evaluating the condition of patients with asthma or rhinitis over the years
Answer each line: YES-NO-X, or with a number, as applicable

| Name: ___________________________________________ | Age: __________________________ |
| Student of: ________________________________ | Profession: __________________________ |

Do you work in a contaminated environment (fumes, oils, irritants)? No [ ] Yes [ ]

Do you smoke? No [ ] Yes [ ] How many cigarettes a day? ______

Do you take part in sports? No [ ] Yes [ ] Which? __________________________
How many days a week? ____________
Do you tolerate sports well? No [ ] Yes [ ]
Do you suffer wheezing or breathing difficulties when doing sports? No [ ] Yes [ ]

How do you feel in relation to your respiratory allergy? Very well [ ] Well [ ] Regular [ ] Poor [ ] Very poor [ ]

Do you have any of the following symptoms? – Wheezing: Every day [ ] In the daytime? [ ] At night? [ ]
Several days a week: How many? ____________
Rarely [ ] Never [ ]
– Breathing difficulty: Every day [ ] In the daytime? [ ] At night? [ ]
Several days a week: How many? ____________
Rarely [ ] Never [ ]
– Cough: Every day [ ] In the daytime? [ ] At night? [ ]
Several days a week: How many? ____________
Rarely [ ] Never [ ]
– Sneezing, itchy nose: Daily [ ] Sometimes [ ] Never [ ]

Do you take medicines for asthma or rhinitis? What medicines? __________________________ Daily [ ] Sometimes [ ] When I feel ill [ ]

Do you have other allergic problems? No [ ] Yes [ ] Urticaria (wheals) [ ] Eczema [ ]

Confirmed allergy to some food? [ ] What food? __________________________
Confirmed allergy to some drug? [ ] What drug? __________________________

To you consider yourself to be cured? No [ ] Yes [ ]

Do you wish to comment something about your allergic illness? __________________________